The Galway-based company earned its funding through the country’s Disruptive Technologies Innovation Fund (DTIF) Call 7 for its PIONEER technology — Pathology and Immuno-Oncology with Next-Generation Screening and Electroporation for Enhanced Response.
PIONEER aims to develop next-generation colorectal cancer treatment based on Mirai’s ePORE electroporation platform. It integrates advanced screening, pathology, molecular profiling and immuno-oncology, the company said in a LinkedIn post. The platform seeks to improve therapeutic response and preserve organ function.
ePORE is a non-thermal pulsed-field ablation (PFA) technology designed to preserve healthy tissue and reduce the need for radical surgery. Mirai designed it to enable the safe and effective treatment of pre-malignant and malignant disease across the GI tract. Through PIONEER, it could aid in organ-preserving treatments for colorectal cancer.
In PIONEER, Mirai collaborates with Trinity College Dublin, University of Galway, University College Dublin, Eurofins and Deciphex. Clinical studies take place at St. James’ Hospital Dublin.
Funding came through Ireland’s Department of Enterprise, Tourism and Employment’s $185 million (€159 million) investment in transformative technologies across health, AI, sustainability and advanced engineering. Enterprise Ireland, the country’s enterprise development agency, recently issued its 2025 MedTech Report, outlining the country’s investment in growth.
IDA Ireland, the foreign investment arm for the Irish government, and Enterprise Ireland, both recently shared the government’s view on medtech’s growth in the country in interviews with MassDevice.
